Joseph Evans

University of Michigan–Ann Arbor — United States

Computer Science · Physical Sciences

24h-index2.6kcitations208works0.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Wireless Communication Networks Research(30), Network Traffic and Congestion Control(25), Cognitive Radio Networks and Spectrum Sensing(17), Opportunistic and Delay-Tolerant Networks(17), Cooperative Communication and Network Coding(16)

Publications208 total

Assessing the Relationship Between MR-Based Functional Dose Metrics and Post-Stereotactic Body Radiation Therapy Albumin-Bilirubin Change
International Journal of Radiation Oncology*Biology*Physics·2025· 1 cited
Editorial
IPPR Progressive Review·2024Open Access
Benefits of Learning Vocal Music with a Systematic Strategy
Journal of Singing·2024
Editorial
IPPR Progressive Review·2024Open Access
Editorial
IPPR Progressive Review·2023Open Access
How to build a country that works for everyone
IPPR Progressive Review·2023Open Access
Is Apparent Diffusion Coefficient Established as an Imaging Biomarker for Stereotactic Body Radiation Therapy Assessment in Hepatocellular Carcinoma?
The Cancer Journal·2023· 1 citedOpen Access
Sup. Fig. 6-8 from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
Sup. Fig. 1- MELK SAGE analysis from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
Supplementary Materials and Methods from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
Data from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
Sup. Fig. 1- MELK SAGE analysis from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
Supplementary Tables 1-3 from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
Supplementary Materials and Methods from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
Sup. Fig. 6-8 from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
Supplementary Figure 9-10 GSEA and MCM from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
Supplementary figure legend from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
Supp Figure 2-5 MELK RNA and protein expression and clonogenic survival from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
Data from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
Supplementary figure legend from Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Gary J. Minden(15), Alexander M. Wyglinski(9), Victor S. Frost(9), Rakesh Rajbanshi(7), Benjamin J. Ewy(6), Timothy R. Newman(5), Daniel DePardo(4), Ricardo Sánchez(4), Monica A. McHenry(4), Brett Barker(3), Arvin Agah(3), B. Liu(3), Leon S. Searl(3), Victor R. Petty(3), Frederick Weidling(3), Dinesh Datla(3), Donna S. Lundy(3), Roy R. Casiano(3), Jun Xue(3), K. Sam Shanmugan(3)